This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Dehaier Medical Develops New Proprietary High-Efficiency Oxygen Inhaler

Stocks in this article: DHRM

BEIJING, June 14, 2012 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that the Company has co-developed its "High-Efficiency Oxygen Inhaler" with Dr. Ding Jianzhang of Beijing Haidian Hospital, which is expected to begin selling in the third quarter of 2012 in mainland China. The portable device is designed for use in homecare oxygen therapy, emergency treatment, disaster relief activities and high-altitude settings.

(Photo: http://photos.prnewswire.com/prnh/20120614/CN24727 )(Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO )

Dr. Ding Jianzhang, the author of "Oxygen Therapeutics & Health", has over 30 years experience, specializing in hyperbaric oxygen treatment. In 2003, he received a patent for an atmospheric oxygen therapy mask. Dehaier obtained an exclusive license to Dr. Ding's patent and has re-designed, developed and used this patent to create the High-Efficiency Oxygen Inhaler. The Inhaler is easily portable and features instantaneous high volume oxygen delivery, while also reducing waste through its uniquely triggered oxygen conveying system. The system supplies oxygen volume automatically according to patient lung capacity and delivers oxygen only on inhalation. The Company is going to apply a patent on its design and technology of this newly-developed High-Efficiency Oxygen Inhaler from the China Patent and Trademark office.

Dehaier Medical's CEO, Mr. Ping Chen commented, "We continue to devote our research and development efforts toward markets where we feel there is a distinct need. After a thorough review, we felt that a portable and efficient solution for individuals with severe oxygenation failure or cerebrovascular disease (blood circulation to the brain) would improve their standard of living and fill a distinct niche in China's medical homecare market. In addition, we expect that our new inhaler will be attractive to athletes such as mountain climbers, emergency rescue personnel and others who need portable and convenient oxygen solutions. We are proud to provide the state of art High-Efficiency Oxygen Inhaler to the market, which again represents our business growth strategy of diversifying sales through shifting focus to homecare medical segment and enriching the product line of home oxygen therapy services. We look forward to realizing considerable sales from the product in near future."

About Dehaier Medical Systems Ltd.

Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD ( Italy), Welch Allyn ( USA), HEYER ( Germany), Timesco (UK), eVent Medical (US) and JMS ( Japan). Dehaier's technology is based on six patents and five software copyrights; additionally Dehaier has two pending software copyrights and proprietary technology. More information may be found at http://www.dehaier.com.cn.



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs